Takeda’s VERDICT Phase 4 trial shows ENTYVIO treat‑to‑target cuts ulcerative colitis complication risk by about 70%
Takeda reported results from the Phase 4 VERDICT study, which randomized adults with moderate‑to‑severe ulcerative colitis to three increasingly strict treatment targets using ENTYVIO. Patients aiming for disease clearance (symptomatic, endoscopic and histologic remission) experienced a hazard ratio of 0.33 for the first UC‑related complication versus those targeting only symptomatic remission. The safety profile remained consistent with earlier ENTYVIO data, and more than half of the participants reached disease clearance by week 16.
Why it matters
The company says the ~70% reduction in complication risk could broaden ENTYVIO’s role in treating ulcerative colitis and support deeper remission goals. The trial’s positive outcome may encourage clinicians to adopt treat‑to‑target strategies, potentially increasing ENTYVIO sales.
Key facts
- 1The trial enrolled 672 patients and assigned them to three groups: symptomatic remission only, symptomatic + endoscopic remission, and symptomatic + endoscopic + histologic remission (disease clearance). stocktitan.net
- 2By week 48, 400 participants (≈60% of the cohort) had achieved their assigned target; 137 in group 1 (74.1%), 125 in group 2 (56.3%) and 138 in group 3 (52.1%). stocktitan.net
- 3The primary endpoint was met, with the disease‑clearance group showing a hazard ratio of 0.33 (95% CI 0.17‑0.67; P = 0.0014) for the first UC‑related complication compared with the symptomatic‑remission group. stocktitan.net
- 4Treat‑to‑target to disease clearance reduced the risk of UC complications by roughly 70% for up to 80 weeks after target achievement. stocktitan.net
- 5Adverse‑event rates were similar across all groups and no new safety signals were identified through 96 weeks of follow‑up. stocktitan.net
- 6Takeda’s shares traded at $19.76 in pre‑market activity, up 0.36% after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.